Background: Presentation with advanced glaucoma is the major risk factor for lifetime blindness. Effective intervention at diagnosis is expected to minimise risk of further visual loss in this group of patients.
Aim: To compare clinical and cost-effectiveness of primary medical management compared with primary surgery for people presenting with advanced open-angle glaucoma (OAG).
Methods: : A prospective, pragmatic multicentre randomised controlled trial (RCT).
Setting: Twenty-seven UK hospital eye services.
Participants: Four hundred and forty patients presenting with advanced OAG, according to the Hodapp-Parish-Anderson classification of visual field loss.
Intervention: Participants will be randomised to medical treatment or augmented trabeculectomy (1:1 allocation minimised by centre and presence of advanced disease in both eyes).
Main Outcome Measures: The primary outcome is vision-related quality of life measured by the National Eye Institute-Visual Function Questionnaire-25 at 24 months. Secondary outcomes include generic EQ-5D-5L, Health Utility Index-3 and glaucoma-related health status (Glaucoma Utility Index), patient experience, visual field measured by mean deviation value, logarithm of the mean angle of resolution visual acuity, intraocular pressure, adverse events, standards for driving and eligibility for blind certification. Incremental cost per quality-adjusted life-year (QALY) based on EQ-5D-5L and glaucoma profile instrument will be estimated.
Results: The study will report the comparative effectiveness and cost-effectiveness of medical treatment against augmented trabeculectomy in patients presenting with advanced glaucoma in terms of patient-reported health and visual function, clinical outcomes and incremental cost per QALY at 2 years.
Conclusions: Treatment of Advanced Glaucoma Study will be the first RCT reporting outcomes from the perspective of those with advanced glaucoma.
Trial Registration Number: ISRCTN56878850, Pre-results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047148 | PMC |
| http://dx.doi.org/10.1136/bjophthalmol-2017-310902 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and clinical associations of relative anterior microphthalmos assessed with an optical biometer.
Sci Rep
December 2024
Department of Ophthalmology, Rajavithi Hospital and College of Medicine, Rangsit University, Bangkok, Thailand.
Relative anterior microphthalmos (RAM) is a rare ocular condition characterized by disproportionately small anterior segments but normal axial length (corneal diameter < 11 mm and axial length > 20 mm). This study aimed to determine the prevalence of RAM and its association with glaucoma utilizing IOL Master 700 data (Carl Zeiss Meditec, Jena, Germany). A retrospective analysis was conducted of the biometric parameters of 6,407 eyes, and 115 cases of RAM were identified.
View Article and Find Full Text PDFOutcomes of non-penetrating deep sclerectomy combined with mitomycin C in advanced open-angle glaucoma in Indian eyes.
Indian J Ophthalmol
December 2024
Department of Glaucoma Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India.
Purpose: To assess the safety and efficacy of non-penetrating deep sclerectomy (NPDS) in advanced open-angle glaucoma patients.
Design: Retrospective observational study.
Methods: Forty-two eyes of 38 patients with advanced glaucoma who underwent NPDS surgery combined with mitomycin-C with or without phacoemulsification were evaluated for up to 12 months at a tertiary eye care center in South India.
Navigating postoperative complications: Uveitis-glaucoma-hyphema syndrome after Ahmed glaucoma valve implantation.
World J Clin Cases
December 2024
Department of Ophthalmology, Hospital Central de San Isidro "Dr. Melchor Angel Posse", Buenos Aires 1641, Argentina.
Altwijri and Alsirhy reported a case of uveitis-glaucoma-hyphema syndrome after an Ahmed glaucoma valve implantation surgery in an advanced primary open-angle glaucoma patient, being the first ever recorded of its kind. The author describes the position of the tube as the origin of the anterior chamber inflammation and hyphema, which resolved shortly after shortening and relocating it. This publication emphasizes the importance of precise implant positioning and close-up patient follow-up after glaucoma filtration surgery as an important standard for healthcare providers.
View Article and Find Full Text PDFArtificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model.
Chin Med J (Engl)
December 2024
Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong 510530, China.
Background: Retinal ganglion cell (RGC) death caused by acute ocular hypertension is an important characteristic of acute glaucoma. Receptor-interacting protein kinase 3 (RIPK3) that mediates necroptosis is a potential therapeutic target for RGC death. However, the current understanding of the targeting agents and mechanisms of RIPK3 in the treatment of glaucoma remains limited.
View Article and Find Full Text PDFShortened Fornix Syndrome After Posterior-Approach Ptosis Repair.
Ophthalmic Plast Reconstr Surg
December 2024
Division of Oculofacial Plastic and Reconstructive Surgery, Shiley Eye Institute, UCSD, La Jolla, California, U.S.A.
Purpose: To describe and characterize shortened fornix syndrome (SFS), a rare complication following posterior-approach ptosis repair using conjunctival Müller muscle resection.
Methods: This retrospective case series evaluates 4 patients who developed SFS after conjunctival Müller muscle resection. Clinical characteristics, surgical histories, management, and outcomes are reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!